Xenograft Model Antitumor Assays
"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
| Descriptor ID |
D023041
|
| MeSH Number(s) |
E05.337.550.200.900 E05.624.850
|
| Concept/Terms |
Xenograft Model Antitumor Assays- Xenograft Model Antitumor Assays
- Tumor Xenograft Assay
- Xenograft Antitumor Assays
- Antitumor Assay, Xenograft
- Antitumor Assays, Xenograft
- Assay, Xenograft Antitumor
- Assays, Xenograft Antitumor
- Xenograft Antitumor Assay
- Antitumor Assays, Xenograft Model
|
Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".
Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".
This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 1 | 3 | 4 |
| 2006 | 1 | 4 | 5 |
| 2007 | 0 | 5 | 5 |
| 2008 | 0 | 4 | 4 |
| 2009 | 0 | 5 | 5 |
| 2010 | 1 | 8 | 9 |
| 2011 | 1 | 9 | 10 |
| 2012 | 0 | 6 | 6 |
| 2013 | 0 | 16 | 16 |
| 2014 | 0 | 13 | 13 |
| 2015 | 1 | 18 | 19 |
| 2016 | 1 | 13 | 14 |
| 2017 | 0 | 14 | 14 |
| 2018 | 2 | 13 | 15 |
| 2019 | 0 | 15 | 15 |
| 2020 | 0 | 9 | 9 |
| 2021 | 1 | 5 | 6 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat Commun. 2023 Mar 13; 14(1):1394.
-
Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in?vitro and in?vivo. Proc Natl Acad Sci U S A. 2022 08 09; 119(32):e2201073119.
-
A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics. J Med Chem. 2022 02 24; 65(4):3420-3433.
-
A bivalent cyclic RGD-siRNA conjugate enhances the antitumor effect of apatinib via co-inhibiting VEGFR2 in non-small cell lung cancer xenografts. Drug Deliv. 2021 Dec; 28(1):1432-1442.
-
TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nat Commun. 2021 09 09; 12(1):5337.
-
The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer. Breast Cancer Res. 2021 06 12; 23(1):65.
-
Selective and noncovalent targeting of RAS mutants for inhibition and degradation. Nat Commun. 2021 05 11; 12(1):2656.
-
Trichodermin Induces G0/G1 Cell Cycle Arrest by Inhibiting c-Myc in Ovarian Cancer Cells and Tumor Xenograft-Bearing Mice. Int J Mol Sci. 2021 May 09; 22(9).
-
Mevalonate Pathway Inhibition Slows Breast Cancer Metastasis via Reduced N-glycosylation Abundance and Branching. Cancer Res. 2021 05 15; 81(10):2625-2635.
-
Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal. Drug Deliv. 2020 Nov 26; 27(1):1729-1740.